The US FDA has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax.

With a population of over 670 million people in ASEAN, the total number of patients experiencing rare diseases and conditions ...

The use of real-world evidence (RWE) began gaining traction decades ago, primarily as a response to the limitation around ...

Corstasis Therapeutics is to collaborate with CVL on the adoption and integration of the Enbumyst nasal spray into heart failure care.

The path from discovery to lifechanging therapy shouldn't be blocked by manufacturing limitations. MasterControl offers ...

During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service ...

As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

Novartis' Stein site will discontinue solid dose manufacturing in favour of sterile dose and cell & gene therapy production, ...

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...